Endocrine Abstracts

Aim: To single out polineuropathy development risk group.

Materials and methods: Four hundred and fifty patients with a more than 5 years diabetes experience were examined.

For verification of a diabetic polyneuropathy the electroneuromyography was made. By a method of the immunofermental analysis neurospecific S100 protein level was defined. Data are presented in Me (Q25; Q75) format. The importance of distinctions was estimated by Mann-Whitney’s criterion.

Results: At 77.3% of patients lesion n. Suralis on axonal type is confirmed. The correlation analysis revealed a direct significant correlation of level of S100 with patient’s age (R Spearman=0.30; P=0.02) and diabetes duration (R Spearman=0.22; P=0.04). At 25.0% of patients axonal antibodies level increase is revealed. Patients with high level of S100 had the disease for more than 10 years. To single out polineuropathy development risk group the examined patients were divided into groups depending on age of demonstration. Patients with diabetes demonstrations age below 14 years (1st group) and from 20 to 30 years (the 2nd group) had the smallest indicators of S100. Levels of neurospecific protein are 24, 00 (21.06; 30.37) ng/l and 31.84 (24.98; 38.20) ng/l respectively and didn’t differ significantly. Patients with more then 40 years diabetes manifestation have 51.11 (36.94; 61.03) ng/l level of S100 which made significant statistical difference with level of (U 360.50; R<0.005) of 1st and 2nd group patients.

Conclusions: Level of axonal antibodies is an early laboratory prognostic marker of development of a sensory diabetic polyneuropathy at patients with diabetes.